207 related articles for article (PubMed ID: 30641027)
1. Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial.
Vogel-Claussen J; Schönfeld CO; Kaireit TF; Voskrebenzev A; Czerner CP; Renne J; Tillmann HC; Berschneider K; Hiltl S; Bauersachs J; Welte T; Hohlfeld JM
Am J Respir Crit Care Med; 2019 May; 199(9):1086-1096. PubMed ID: 30641027
[No Abstract] [Full Text] [Related]
2. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
3. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Singh D; Wild JM; Saralaya D; Lawson R; Marshall H; Goldin J; Brown MS; Kostikas K; Belmore K; Fogel R; Patalano F; Drollmann A; Machineni S; Jones I; Yates D; Tillmann HC
Respir Res; 2022 Feb; 23(1):26. PubMed ID: 35144620
[TBL] [Abstract][Full Text] [Related]
4. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
[TBL] [Abstract][Full Text] [Related]
5. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Watz H; Mailänder C; Baier M; Kirsten A
BMC Pulm Med; 2016 Jun; 16(1):95. PubMed ID: 27301417
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.
Lehmann S; Ringbæk T; Løkke A; Grote L; Hedner J; Lindberg E
Int J Chron Obstruct Pulmon Dis; 2019; 14():199-210. PubMed ID: 30666100
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
8. Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Tsiligianni I; Mezzi K; Fucile S; Kostikas K; Shen S; Banerji D; Fogel R
COPD; 2017 Aug; 14(4):375-381. PubMed ID: 28594587
[TBL] [Abstract][Full Text] [Related]
9. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
[TBL] [Abstract][Full Text] [Related]
12. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
13. Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.
Tashkin DP; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Respir Med; 2019 Aug; 155():113-120. PubMed ID: 31344660
[TBL] [Abstract][Full Text] [Related]
14. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
[TBL] [Abstract][Full Text] [Related]
16. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
Santus P; Radovanovic D; Di Marco F; Raccanelli R; Valenti V; Centanni S
Pulm Pharmacol Ther; 2015 Dec; 35():42-9. PubMed ID: 26549785
[TBL] [Abstract][Full Text] [Related]
17. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Salomon J; Stolz D; Domenighetti G; Frey JG; Turk AJ; Azzola A; Sigrist T; Fitting JW; Schmidt U; Geiser T; Wild C; Kostikas K; Clemens A; Brutsche M
Respir Res; 2017 Jan; 18(1):13. PubMed ID: 28077140
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
19. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial.
Santus P; Radovanovic D; Di Marco S; Valenti V; Raccanelli R; Blasi F; Centanni S; Bussotti M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1917-23. PubMed ID: 26392766
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE.
Asai K; Hirata K; Hashimoto S; Fukuchi Y; Kitawaki T; Ikeda K; Fogel R; Banerji D
Respir Investig; 2016 Nov; 54(6):428-435. PubMed ID: 27886854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]